SCHEMBL15580751

SCHEMBL15580751

COC(=O)N[C@@H](CC(=O)C(C)(C)C)Cc1cccs1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.45
CTSS P25774 1/20 0.45
CTSK P43235 1/20 0.45
CYP2C19 P33261 2/20 0.43
CTSC P53634 3/20 0.42
CYP3A4 P08684 2/20 0.42
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
PKM P14618 1/20 0.40
NPC1 O15118 4/20 0.39
LMNA P02545 3/20 0.39
HTT P42858 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
RECQL P46063 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
HPGD P15428 2/20 0.39
CYP1A2 P05177 1/20 0.39
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22361398 1.00 RAB9A (0.45) RAB9ACTSSCTSKCYP2C19CTSC
SCHEMBL11982189 0.85 CYP2C19 (0.50) RAB9ACTSSCTSKCYP2C19CTSC
SCHEMBL756370 0.85 CYP2C19 (0.50) RAB9ACTSSCTSKCYP2C19CTSC
SCHEMBL755382 0.85 CYP2C19 (0.50) RAB9ACTSSCTSKCYP2C19CTSC
SCHEMBL14864789 0.85 RAB9A (0.48) RAB9ACTSSCTSKCYP2C19CTSC
SCHEMBL14864692 0.85 RAB9A (0.48) RAB9ACTSSCTSKCYP2C19CTSC
SCHEMBL12755477 0.83 RAB9A (0.49) RAB9ACTSSCTSKCYP2C19CTSC
SCHEMBL12755478 0.83 RAB9A (0.49) RAB9ACTSSCTSKCYP2C19CTSC
SCHEMBL10120447 0.79 ATM (0.52) RAB9ACTSSCYP3A4NPC1
SCHEMBL8908191 0.79 ATM (0.52) RAB9ACTSSCYP3A4NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10752611-B2 Benzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2020-08-25 US disclosed
US-9127021-B2 Hepatitis C virus inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2015-09-08 US disclosed
US-8673954-B2 Benzimidazole derivatives ENANTA PHARMACEUTICALS, INC. (US) 2014-03-18 US disclosed
US-20110300104-A1 HEPATITIS C VIRUS INHIBITORS ENANTA PHARMACEUTICALS, INC. 2011-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110300104-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, SLC10A1, EIF2AK2 RAB9A 3036/4885CTSS 571/4885CTSK 933/4885
US-10752611-B2 Benzimidazole derivatives EIF2AK2, ZC3HAV1, ZC3HAV1L RAB9A 3990/4885CTSS 853/4885CTSK 1129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.